about
Oligomycin frames a common drug-binding site in the ATP synthase.The yeast mitochondrial citrate transport protein. Probing the roles of cysteines, Arg(181), and Arg(189) in transporter functionIntroduction of the chloroplast redox regulatory region in the yeast ATP synthase impairs cytochrome c oxidase.The mitochondrial citrate transport protein: probing the secondary structure of transmembrane domain III, identification of residues that likely comprise a portion of the citrate transport pathway, and development of a model for the putative TMDIII-Inhibitors of the mitochondrial citrate transport protein: validation of the role of substrate binding residues and discovery of the first purely competitive inhibitor.Ion selectivity of alpha-hemolysin with beta-cyclodextrin adapter. II. Multi-ion effects studied with grand canonical Monte Carlo/Brownian dynamics simulations.Probing the effect of transport inhibitors on the conformation of the mitochondrial citrate transport protein via a site-directed spin labeling approach.Mitochondrial and Plasma Membrane Citrate Transporters: Discovery of Selective Inhibitors and Application to Structure/Function AnalysisDesign and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.A conserved arginine near the filter of Kir1.1 controls Rb/K selectivity.Regulation of ROMK by extracellular cationsStructural locus of the pH gate in the Kir1.1 inward rectifier channel.Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.Antipsychotics inhibit glucose transport: Determination of olanzapine binding site in Staphylococcus epidermidis glucose/H(+) symporter.External K activation of Kir1.1 depends on the pH gateProperties of two cataract-associated mutations located in the NH2 terminus of connexin 46.An intersubunit salt bridge near the selectivity filter stabilizes the active state of Kir1.1.The yeast mitochondrial citrate transport protein: identification of the Lysine residues responsible for inhibition mediated by Pyridoxal 5'-phosphate.Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.Binding of glutamate to the umami receptor.The mitochondrial citrate transport protein: evidence for a steric interaction between glutamine 182 and leucine 120 and its relationship to the substrate translocation pathway and identification of other mechanistically essential residues.Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases.Genetically evolved receptor models: a computational approach to construction of receptor models.Presence of the anti-leukemic nucleotide analog, 2-chloro-2'-deoxyadenosine-5'-monophosphate, in a promoter sequence alters DNA binding of TATA-binding protein (TBP).Structure and dynamic behavior of the oligosaccharide side chain of bovine pancreatic ribonuclease B. Application of carbon 13 nuclear magnetic resonance spectroscopyTautomeric states of the histidine residues of bovine pancreatic ribonuclease A. Application of carbon 13 nuclear magnetic resonance spectroscopyPredictive models of protein-active sitesOligomeric state of wild-type and cysteine-less yeast mitochondrial citrate transport proteinsActive conformations of neotame and other high-potency sweetenersThe yeast mitochondrial citrate transport protein. Probing the secondary structure of transmembrane domain iv and identification of residues that likely comprise a portion of the citrate translocation pathwayThe active site of pyrophosphate-dependent phosphofructo-1-kinase based on site-directed mutagenesis and molecular modelingThe yeast mitochondrial citrate transport protein: determination of secondary structure and solvent accessibility of transmembrane domain IV using site-directed spin labelingIdentification of the substrate binding sites within the yeast mitochondrial citrate transport proteinMolecular dynamics study of a polymeric reverse osmosis membraneOrexin Antagonists: A Wake-Up Call for Medicinal Chemists?Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation
P50
Q27671306-0F658B73-6F48-4A2A-AE2A-B79B5417E3E4Q28372210-DFB9D019-8AF3-4AC8-9F7B-7C7643E96DBAQ30484585-94F4135B-E315-43FD-9033-A7B0ACD3A866Q30882330-8398F658-80DE-4C9C-BBD2-7EEBE5DDFF69Q33574703-954D85FB-6247-4BA3-894A-48CE65523F7DQ33746942-55C51753-5640-48B0-A570-8E876E91351FQ33841608-8A3286DC-909D-4DE4-AC78-EE505E1C5119Q34034000-1378D94A-2650-4AFB-9AE0-E4718D3AB2C8Q34046931-88853A8C-6187-47DA-B07B-DC5AC13096F9Q34112654-1B89CD8C-9621-45DA-BF44-A4ED619BE2EBQ34174925-F385584A-2BB7-4DD8-9AD1-D89526B7DC5FQ34189737-697C95F9-4081-4A73-B181-9FFCD417A601Q34507768-FB09E110-44F3-44EA-8522-802EBC1533C9Q35547830-61ED6D6F-14D9-46BE-B674-23E2525B9692Q35850979-D20E3681-B92C-426D-A117-3AEDA36A864DQ36836123-D24D1431-9223-4AA2-A075-BB9EB42E636AQ37303911-7B8B1A76-BD56-4556-A9C2-0152CA451D37Q37417174-2BC9D99C-8ECB-4D36-B107-D0AE44FA8279Q40423917-E7654E2F-C302-4D72-A1AC-A67208BB51C4Q42852717-BDFFCBBF-4C89-448E-AEBC-E3AED5923451Q50105800-BFFDF641-E937-4DE9-9F9F-E12F6A986AEEQ50217036-FE609E0C-3AC2-40CB-BE3F-4383AA46C4FEQ52372780-E368172B-E981-4C85-BC07-390C8B08D9F6Q52577251-1A0E393B-DE11-4452-876D-94223A956F7DQ70729944-12FDF96C-A221-4C9E-AF95-B239180C0238Q71241866-6C567C1E-8A7E-4E27-9FB5-74D6D67EC1EEQ73206485-9CA5752D-B3C1-42C1-AF11-CD7E0F300102Q73465656-B51F6ABD-96FB-4A74-B07A-369C8565673CQ73594147-9A9A79A6-684C-4D24-8D79-FE88BD529501Q73680602-A68A6CE3-F3BE-4FCD-969C-CD40EF4E4D9BQ74079154-A16E40A6-1C33-4C45-A286-2892569235C9Q74103959-F030A31C-BF5A-46E9-BD7D-E49D3CCF2B65Q80075456-DE975A86-72A4-40EE-840B-0CCA304D5676Q84194951-754E5C6C-C79B-4BBE-AD78-75B23D84A1C9Q89774974-1F9A5CD5-3CF0-44E0-A6E7-90EA6AC24CE7Q92644988-F7A1191A-767B-477A-8DC3-6B6FD5E0B788
P50
description
researcher
@en
name
D. Eric Walters
@en
Walters DE
@nl
type
label
D. Eric Walters
@en
Walters DE
@nl
altLabel
Walters DE
@en
prefLabel
D. Eric Walters
@en
Walters DE
@nl
P106
P31
P496
0000-0002-1513-3522